Atypical Nevi

Medical reports indicate that at least 20 million Caucasians in the U.S. have atypical nevi. While benign, dysplastic nevi may serve as identification markers for patients who are at an increased risk for developing melanoma. The lifetime risk of a person in the U.S. developing melanoma is 1 in 75. A patient with a single atypical nevus and no personal or close family history of melanoma is at a slightly greater risk of developing melanoma than the general population. However, a patient with multiple atypical nevi and a personal or family history of melanoma are at a significantly greater risk of developing melanoma and may meet the criteria for Familial Atypical Mole Syndrome.

The National Institute of Health Consensus Conference has defined Familial Atypical Mole Syndrome as those patients with the following criteria:

• A first-degree (e.g., parent or child) or second-degree (e.g., grandparent, grandchild, aunt or uncle) relative with a melanoma.
• A large number of nevi, often more than 50, some of which are atypical.
• Nevi which have atypical or dysplastic changes microscopically.

A patient with Familial Atypical Mole Syndrome is at a significantly greater risk of developing melanoma. Both the number of nevi and the number of family members with melanoma independently affect the risk of developing melanoma.

Patients with multiple atypical nevi should examine their own skin on a monthly basis, and should have a thorough head to toe examination by a dermatologist at least annually. Photographs are sometimes taken to monitor the appearance of dysplastic nevi. Any mole that undergoes a significant change in size, shape, or color or develops symptoms of itching or burning should be suspected of being a melanoma and should promptly be evaluated by a dermatologist.